WHO ICTRP trial
EVEREST: EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2…
EUCTR2021-000829-27-FR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2021-000829-27-FR |
|---|---|
| Public title | EVEREST: EValuating trEatment RESponses of dupilumab versus omalizumab in Type 2 patients |
| Scientific title | A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients - EVEREST |
| Primary sponsor | Sanofi-aventis Recherche & Développement |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Romania;Hungary;United States;Czechia;United Kingdom;Portugal;Spain;Sweden;Czech Republic;Belgium;Finland;Denmark;Poland;Italy;France;Germany |
| Conditions | Chronic rhinosinusitis with nasal polyps MedDRA version: 20.1 Level: PT Classification code 10080060 Term: Chronic rhinosinusitis with nasal polyps System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic… |
| Interventions | Product Name: Dupilumab Product Code: SAR231893 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Dupilumab Current Sponsor code: SAR231893 Other descriptive name: REGN668 Concentration unit: mg/ml… |
| Registration date | Jul 6, 2021 |
| Target size | 844 |
| Secondary IDs | LPS16747 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: